The National Cancer Clinical Trials Collaborative Learning Network (CCTCLN)
Cancer Clinical Trials Collaborative Learning Network
We are pleased to invite sites accruing patients to cancer clinical trials to participate in our Collaborative Learning Network (CCTCLN). A follow-up to our Pilot Breakthrough Collaborative completed in 2012, the Network is funded by leading research pharmaceutical companies committed to helping sites use a quality improvement approach to increasing accrual to cancer treatment trials. The goal of the CCTCLN is to build on the Pilot to identify practical, patient-centered approaches to increase accrual, particularly for ethnic /racial minorities and people over 65.
Thank you to our funders!
Participation in cancer treatment clinical trials (CCTs) is a key measure for delivery quality cancer care, yet adult trial participation in the U.S. remains under 3%, with even lower participation rates among ethnic and racial minorities and people over 65. If institutions are to be evaluated by the access they provide to CCTs—such as through the Commission on Cancer’s 2015 guidelines--it is critical to employ effective accrual practices that are grounded in evidence. Unfortunately, there are few evidence-based practices to help sites achieve higher accrual rates. ENACCT is creating this evidence through its leadership of the Cancer Clinical Trial Collaborative Learning Network (CCTCLN).
The CCTCLN is built upon the successful work of the National Pilot Collaborative completed in 2012. The goal of the CCTCLN is to further the goal of the Pilot: to identify practical, patient-centered approaches to increase accrual overall and, in particular, for ethnic /racial minorities and people over 65.
Participation in the Network will provide research teams with tools and techniques to identify and capitalize on specific opportunities for improvement to expand accrual and increase efficiency with limited clinical research budgets. Over the course of 4 months, the CCTCLN will provide institutions with the skills and tools it needs to begin to improve recruitment and accrual. Specifically, this process will provide:
- education and training of staff in quality improvement techniques in the context of clinical trials;
- assessment of clinical trial “ecosystem” including research culture, trial portfolio, accrual processes, communication effectiveness, staff capacity, operational benchmarks and community outreach;
- a process map delineating bottlenecks and opportunities for improvement;
- an action plan to improve accrual results;
- a peer network to share experiences and lessons and avoid problems and mistakes;
- coaching and expertise to expedite and focus efforts; and
- guidance to help implement practice changes to increase accrual and clinical trial revenue.
No matter how well your institution is doing around cancer trials accrual, being part of this Network will provide the opportunity to do even better.
Any institution (non-profit or for profit) currently treating cancer patients and already offering phase II-III cancer treatment trials for adults and adolescents. Such institutions can be a:
- hospital-based cancer center
- cancer center based in an academic institution
- NCI designated Cancer Center
- community oncology practice
- CCOP, MBCCOP or other coordinating network, as long as a central site manages satellite sites and administers policies and procedures at all locations
In addition, the institution must:
- either have a hospital affiliation or be a distinct hospital program within a separate physical setting;
- offer comprehensive cancer care or have a strong relationship with radiation and surgical oncology;
- be located in the U.S. or its territories; and
- be committed to the quality improvement process and participation in all training and development activities.
- Learn more about the National Cancer Clinical Trials Pilot Collaborative & Access the Final Report
- Learn more about the Institute for Healthcare Improvement (IHI) Breakthrough Collaborative Series
- Contact Us:
- 301-893-7603 ext. 701